A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group Study by Coleman, Robert L. et al.
A phase II evaluation of nanoparticle, albumin-bound (nab)
paclitaxel) in the treatment of recurrent or persistent platinum-
resistant ovarian, fallopian tube, or primary peritoneal cancer: A
Gynecologic Oncology Group Study
Robert L. Coleman, MD1, William E. Brady, MS2, D. Scott McMeekin, MD3, Peter G. Rose,
MD4, John T. Soper, MD5, Samuel S. Lentz, MD6, James S. Hoffman, MD7, and Mark S.
Shahin, MD8
1 Department of Gynecologic Oncology, University of Texas, MD Anderson Cancer Center,
Houston, TX 77030
2 Gynecologic Oncology Group Statistical & Data Center; Roswell Park Cancer Institute; Buffalo,
NY 14263
3 Division of Gynecologic Oncology, University of Oklahoma, Oklahoma City, OK 73190
4 Division of Gynecologic Oncology; Cleveland Clinic Foundation; Case Western Reserve
University; Cleveland, OH 44195
5 Division of Gynecologic Oncology; University of North Carolina, Chapel Hill NC 27599
6 Division of Gynecologic Oncology; Wake Forest University; Winston-Salem, NC 27157
7 The Hospital of Central Connecticut Gynecologic Oncology; New Britain, CT 06050
8 Division of Gynecologic Oncology; Abington Memorial Hospital; Abington, PA 19001
Abstract
Background—Nab-paclitaxel is a novel Cremophor®-free nanoparticle of albumin-stabilized
paclitaxel, which has favorable efficacy and toxicity characteristics relative to other solvent-based
taxanes, such as paclitaxel and docetaxel.
Methods—Eligible patients had platinum- and taxane-resistant ovarian cancer, defined by
persistent or progressive disease following primary chemotherapy (n=5) or recurrence within six
months of treatment completion (n=42). All patients had measurable disease, no prior therapy for
recurrent disease and Gynecologic Oncology Group performance status of ≤ 2. Treatment was
nab-paclitaxel, 100 mg/m2 days 1,8,15 on a 28-day schedule. The primary endpoint was Response
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Evaluation Criteria in Solid Tumors v1.0 response rate, evaluated in a 2-stage design (with power
of 0.90 for a RR of 25% and with alpha of 0.05 for RR of 10%).
Results—Fifty-one patients were enrolled of which 47 were evaluable; median time from
frontline therapy completion to registration was 21 days. Patient demographics include median
age: 59 (34–78) years, serous histology: 72%, and high-grade: 81%. Efficacy: One complete and
10 partial responses were confirmed (23%); 17 patients (36%) had stable disease. The median
progression-free survival was 4.5 months (95%CI: 2.2–6.7); overall survival was 17.4 months
(95%CI: 13.2–20.8). Seventeen patients (36%) had PFS>six months. Toxicity: there were no
grade 4 events; grade 3 events were neutropenia (6), anemia (3), GI (2), metabolic (2), pain (2),
and leukopenia (1); neurosensory toxicity was observed as grade 2:5, grade 3:1.
Conclusions—Nab-paclitaxel has noteworthy single-agent activity and is tolerable in this cohort
of refractory ovarian cancer patients previously treated with paclitaxel.
Keywords
ovarian cancer; fallopian tube cancer; primary peritoneal cancer; platinum-resistant; taxane-
resistant; nab-paclitaxel
INTRODUCTION
Emergence of drug resistance is responsible for the majority of deaths due to recurrent
ovarian cancer. Further complicating this clinical observation is the approximately 25% of
patients in whom platinum and taxane resistance are a phenotype of their primary disease
[1]. This has bolstered the continuous search for novel cytotoxic and biologic compounds
targeting multiple aspects of the tumor microenvironment.
As a class, the taxanes remain a foundation of primary and recurrent ovarian cancer
management strategies. In 1996, paclitaxel was found to result in superior progression free
(PFS) and overall (OS) survival in women with suboptimally-cytoreduced ovarian cancer in
combination with cisplatin compared to cyclophosphamide + cisplatin [1]. Since this time,
the agent has found ubiquitous use in gynecologic malignancies, including recurrent ovarian
cancer. Furthermore, other taxane analogues have been described to have clinical activity
alone and in combination with other cytotoxics and biological agents in this setting.
The Gynecologic Oncology Group (GOG) has serially investigated several cytotoxic agents
in the setting of measurable platinum- and taxane-resistant recurrent ovarian cancer (the
GOG 126-queue). To date, 13 compounds have undergone objective evaluation for clinical
efficacy in this cohort of women. In these sequentially conducted studies, eligibility criteria
and evaluation methodology have remained essentially unaltered, providing a unique
historical perspective of efficacy and toxicity, while sparing patient resources. From this
investigation, two taxanes, docetaxel and paclitaxel (weekly administration), and
pemetrexed have demonstrated sufficient clinical activity to merit further clinical evaluation
[2–4]. Herein, we report on the fourth agent, nab-paclitaxel (ABI-007).
Nab-paclitaxel is a novel clinical entity incorporating paclitaxel into an albumin
nanoparticle. In this solvent-free formulation, paclitaxel exhibits linear pharmacokinetics,
can be administered without hypersensitivity premedication and has been associated in
preclinical models with higher intratumoral concentrations of paclitaxel relative to the
Cremaphor®-EL (Cr-EL) paclitaxel administration. This latter observation is due to
transendothelial cell transport of albumin sinks around tumor [5–7]. Heightened efficacy has
been observed in a number of solid tumors, most notably, metastatic breast cancer, where
the agent is Food and Drug Administration (FDA) approved. Current administration
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guidelines have suggested that a higher therapeutic ratio can be achieved by administering
nab-paclitaxel weekly as opposed to its bolus infusion [6–9]. Thus, given the previous
documented clinical efficacy of weekly paclitaxel in patients with recurrent, platinum- and
taxane-resistant ovarian cancer, we sought to investigate the efficacy of weekly nab-
paclitaxel in this setting.
METHODS
Patients
Consistent with other agents evaluated in the GOG 126-series, patients were required to
have recurrent or persistent epithelial ovarian, primary peritoneal or fallopian tube
carcinoma. All patients were required to be considered platinum- and taxane-resistant or
refractory according to standard GOG criteria, i.e., have had a treatment-free interval
following platinum/taxane therapy of less than 6 months, have persistent disease at the
completion of primary platinum- and taxane-based therapy or have progressed during this
therapy. Histological confirmation of the original primary tumor by review of the pathology
reports was required. All patients were required to have measurable disease, defined as at
least one lesion that could be accurately measured in at least one dimension (longest
dimension to be recorded). Each lesion must have been ≥ 20 mm when measured by
conventional techniques, including palpation, plain x-ray, CT, and MRI, or ≥ 10 mm when
measured by spiral CT. Patients were required to have at least one “target lesion” to be used
to assess response as defined by Response Evaluation Criteria in Solid Tumors (RECIST)
(version 1.0). Patients were to have a GOG Performance Status of 0, 1, or 2; have recovered
from effects of recent surgery, radiotherapy, or chemotherapy; and be free of active infection
requiring antibiotics. Any hormonal therapy directed at the malignant tumor was to be
discontinued at least one week prior to registration; however, continuation of hormone
replacement therapy was permitted. Any other prior therapy directed at the malignant tumor,
including biological, immunologic agents or radiation therapy, was to be discontinued at
least three weeks prior to registration. Allowable initial treatment included high-dose
therapy, consolidation, or extended therapy administered after surgical or non-surgical
assessment. However, patients were not allowed to receive any additional cytotoxic
chemotherapy for management of recurrent or persistent disease, including retreatment with
initial chemotherapy regimens. Patients are allowed to receive, but are not required to
receive, one additional non-cytotoxic regimen for management of recurrent or persistent
disease. Patients were required to have adequate bone marrow function and blood
chemistries.
Patients were considered ineligible if they had been previously exposed to nab-paclitaxel;
received radiation to more than 25% of marrow-bearing areas; had uncontrolled
hypertension, uncompensated congestive heart failure, symptomatic coronary artery disease,
or myocardial infarction within six months. Patients with a history of other invasive
malignancies, with the exception of non-melanoma skin cancer, were excluded if there was
any evidence of another malignancy within the last 5 years. Finally, all patients were
required to provide a written informed consent consistent with all federal, state and
institutional investigational requirements prior to receiving protocol therapy.
Treatment Plan
Eligible patients enrolled onto this Phase II study received nab-paclitaxel 100 mg/m2,
intravenously over 30 minutes every seven days on days 1, 8, and 15 of a 28-day cycle. No
premedication for the prevention of hypersensitivity reaction (HSR), nausea or vomiting was
required but could be administered based on emerging or apparent clinical symptomatology.
The maximal body surface area used for dose calculations was 2.0 m2. Patients were
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allowed to continue on therapy indefinitely until: (1) withdrawal of consent, (2) evidence of
disease progression or (3) significant side effects precluding further administration, (4)
inability to tolerate the lowest doses due to toxicity.
Treatment Modifications
Hematologic toxicity—Initial treatment modifications consisted of cycle delay and/or
dose reduction depending on the severity and duration of the individual toxicity or toxicities
attributable to the investigational agent. The use of hematopoietic cytokines and protective
reagents [e.g. filgrastim (G-CSF), sargramostim (GM-CSF), and pegfilgrastim] was
restricted to those patients who experienced recurrent neutropenic complications despite
dosing and delay modifications. Treatment modifications were based on the absolute
neutrophil count (ANC) rather than the total white cell count (WBC). Subsequent cycles of
therapy were not allowed to be infused until the ANC was greater than or equal to 1500
cells/mcl (CTCAE v3.0 grade 1) and the platelet count was ≥ 100,000/mcl. Therapy could
be delayed for a maximum of 2 weeks in response. However, patients who failed to recover
adequate counts after a two-week delay will be removed from study. Patients experiencing a
first occurrence of febrile neutropenia, and/or documented grade 4 neutropenia persisting ≥
7 days, underwent a one dose level reduction (dose level -1: 80 mg/m2, dose level -2: 60 mg/
m2) in nab-paclitaxel dosage for subsequent cycles. For recurrent febrile neutropenia, and/or
recurrent documented grade 4 neutropenia persisting ≥ 7 days (after initial dose reduction),
prophylactic growth factors were to be administered. Patients with grade 4
thrombocytopenia were also to undergo a 1 level dose reduction.
Non-hematologic toxicity—Grade 2 (or greater) peripheral neuropathy required a
reduction of 1 dose level (to 80 mg/m2) and delay in subsequent therapy for a maximum of 2
weeks until recovered to grade 1. This modification was also required for a grade 2 (or
greater) renal toxicity. Grade 3 (or greater) elevations in SGOT (AST), SGPT (ALT),
alkaline phosphatase or bilirubin required a reduction of 1 dose level and delay in
subsequent therapy for a maximum of 2 weeks until recovered to grade 1. Non-hematologic
toxicities with an impact on organ function of grade 2 (or greater) required a reduction of 1
dose level and delay in subsequent therapy for a maximum of 2 weeks until recovered to
grade 1, or pre-therapy baseline. While routine premedication to prevent hypersensitivity,
nausea, or vomiting was not required, hypersensitivity reactions have been observed in some
patients treated nab-paclitaxel. Patients experiencing a severe hypersensitivity reaction,
immediate termination of the infusion and administration injectable steroids and epinephrine
was recommended, as well as customary patients supportive care. Patients with grade 3
hypersensitivity reactions were allowed to undergo retreatment after standard paclitaxel
premedication at the discretion of the investigator. No dose escalations or re-escalations
were allowed on this study and intolerance of level -2 dosing (60 mg/m2) necessitated
removal from study.
Study parameters and Method of Evaluation
Following registration but before first infusion, patients were to undergo a complete history
and physical exam, including a bimanual pelvic evaluation, clinical tumor assessment, pre-
existing toxicity assessment, routine hematological and blood chemistries, chest imaging
(chest radiograph or computed tomography of the thorax), radiograph tumor measurement
(for RECIST 1.0 “target lesion(s)”), serum CA125 and, where appropriate, a serum
pregnancy test. A CBC and differential were obtained weekly on therapy, with other
laboratory blood testing (similar to baseline) obtained prior to each treatment cycle (28
days).
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Standard GOG-RECIST (v1.0) criteria were utilized to evaluate response and progression on
this trial. All documented responses were required to undergo confirmation by imaging and/
or exam no sooner than 4 weeks following the initial documentation of response. PFS was
calculated from study entry until documented disease progression, death or date of last
contact. OS was defined from the date of study entry until death or date of last contact.
Statistical Considerations
The primary endpoint of this study was frequency of objective tumor response. Secondary
endpoints included frequency and severity of adverse effects, and duration of PFS and OS.
The study used a flexible, 2-stage accrual design that allowed stopping early for lack
treatment activity [8]. During the first stage of accrual, 19 to 26 patients were to be entered
and evaluated; if >=3 of 19–25 or <=42 of 26 patients had a complete (CR) or partial
response (PR), a second phase of accrual was to be initiated, with a total 2-stage accrual of
44 to 51 patients. The regimen would be considered active if at >=7 of 44–45 or >=8 of 46–
51 patients had a PR or CR. If the true response rate were 10%, the average probability of
designating the treatment as active would be limited to 10%; on the other hand, if the true
response rate were 25%, the probability of correctly classifying the treatment as active
would be 90%.
RESULTS
A total of 51 patients were enrolled onto this multi-institution cooperative group clinical
trial. Three patients were ineligible, due to improper pre-protocol treatment (1), patient not
platinum resistant (1), and wrong stage (1). In addition, 1 patient never received study agent.
Table 1 presents the characteristics of the eligible and treated patients. While all of the
patients on this study were platinum- and taxane-resistant by definition (time from primary
treatment completion to first recurrence less than 6 months), a substantial proportion (n =
33, 70%) recurred within 3 months of primary treatment completion, including 6 patients, or
13%, who had increasing disease while on primary platinum and taxane chemotherapy. The
median treatment-free interval for the treatment cohort was just 21 days (excluding 5
patients who had persistent, not recurrent, disease. In addition, 12 (26%) had been
previously exposed to bevacizumab.
The median number of cycles administered was 4 (range: 1–40); the most common reason
for treatment discontinuation was disease progression occurring in 42 (82%) patients;
treatment-associated toxicity, physician preference and patient preference accounted for 3
(6%), 3 (6%) and 2 (4%) additional patients, respectively.
Table 2 presents the adverse events attributable to the study agent observed in the study.
Severe adverse events were uncommon, including myelosuppression, in which no grade 4
toxicities were observed. In addition, severe non-hematological toxicities were infrequently
experienced. Neurotoxicity was observed as grade 2 in 5 patients (11%) and grade 3 in 1
patient (2%). No grade 3 fatigue was reported in this cohort, however, 15 (32%) reported
grade 2 symptoms. Nine patients had a total of 17 treatment delays (each of 7–14 days
duration); of the individual instances of delays: 9 were due to protocol-related adverse
events; 3 were due to non-protocol illness, and 5 were due to personal reasons or scheduling.
Five patients were dose reduced to 80 mg/m2, and one of these was further reduced to 60
mg/m2.
Of the 47 patients evaluable for efficacy, 11 (23%, 95% CI: 12% – 38%) were identified
with confirmed responses (1 complete response and 10 partial responses); another 17
patients (36%) had stable disease. When stratified by a treatment-free interval following
primary chemotherapy of 0–3 and 3–6 months, response rates were: 21% (7/33) and 29%
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(4/14), respectively. Of the 12 patients progressing despite carboplatin, paclitaxel and
bevacizumab, two (17%) achieved response. In all, 18 patients (38%) were progression-free
more than 6 months. The median PFS and OS were 4.5 months (95% CI: 2.2–6.7 months)
and 17.4 months (95% CI: 13.2–20.8 months), respectively, and are presented in Figure 1.
At this point, 19 patients were alive, 4 without progression; 23 patients had died as a result
of disease progression.
DISCUSSION
In this multi-institutional phase II, we identified that nab-paclitaxel, administered by weekly
infusion is associated with significant clinical activity (objective response: 23%) and
survival characteristics (PFS: 4.5 months, OS: 17.4 months). These parameters are
particularly noteworthy given the treatment population, which was predominately refractory
heralded by a median platinum and taxane-free interval of 21 days and 70% of patients
recurring within 3 months of primary treatment completion. In addition, 12 patients
enrolling in this trial had progressed despite exposure bevacizumab. Further, despite the
short off-treatment interval prior to participation, severe hematological and non-
hematological toxicities were infrequently observed, including neurotoxicity.
The investigational agent is a novel nanoparticle formulation of paclitaxel. The impetus to
develop this compound was to optimize use of paclitaxel in a Cremophor®-free setting,
which could simplify administration by allowing conventional tubing, provide linear
pharmacokinetics, and potentially reduce toxicity (e.g. hypersensitivity reactions,
neurotoxicity, etc) associated with the solvent [5, 6, 8–10]. In addition, nab-paclitaxel was
developed to capitalize on the transendothelial cell transport of albumin which is mediated
by the glycoprotein gp60 receptor and caveolar transport. Albumin binds to gp60 and
activates CAV1 which induces caveoli formation [11]. Albumin and other plasma
constituents migrate across the endothelial cell membrane to the interstitial space. The
relevance of this mechanism in cancer therapy stems from the clustering of albumin in
tumors by SPARC (secreted protein acidic and rich in cysteine or osteonectin), which binds
albumin with high affinity and is overexpressed in many tumor types [12]. Mechanistically
this effect has been associated with higher intra-tumoral concentrations of paclitaxel when
delivered as nab-paclitaxel relative to Cr-EL paclitaxel. In addition, free paclitaxel in serum
following nab-delivery was 5.4 fold reduced compared to tumor concentrations and 2.2 fold
lower in normal tissues, accounting for its higher therapeutic ratio relative to Cr-EL
paclitaxel [13].
Nab-paclitaxel has been previously studied in platinum-sensitive recurrent ovarian cancer
patients both as a single agent and in combination with carboplatin. In the single-agent phase
II study, 44 evaluable patients (measurable and CA125 assessable) were treated with nab-
paclitaxel 260 mg/m2 intravenously over 30 minutes every 21 days for 6 cycles or
progression [14]. Prior taxane exposure was 89%, and 92% of patients had a platinum-free
interval of greater than 12 months. Overall RR was 64%, including 15 patients (34%) with a
complete response. Median PFS was 8.5 months. Severe adverse events were infrequent
despite the dose, including 11% grade 4 neutropenia, 2% grade 3 fatigue and 13% grade 2–3
neuropathy. No HSRs were recorded. In a second phase II study, recently reported in
abstract form, nab-paclitaxel (100 mg/m2, days 1, 8, 15) was administered in combination
with carboplatin (AUC 5, day 1) on a 28-day schedule [15]. All evaluable patients (n = 38)
were previously exposed to taxane/platinum therapy (median treatment-free interval: 13
months), had measurable recurrent disease and were treated for at least 6 cycles or until
progression. Overall RR was 78%, equally divided as complete and partial responses. The
median PFS and OS were 13 months and 30 months, respectively. The most common
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toxicities reported were grade 3–4 neutropenia (43%), fatigue (33%) and hypersensitivity to
carboplatin (18%).
Prior to this study’s initiation, no prior reports of nab-paclitaxel in either infusion schedule
were available in women with platinum- and taxane-resistant ovarian cancer. However,
clinical efficacy of nab-paclitaxel administered weekly, appears to be consistent with the
clinical efficacy of its parent compound in this setting. Weekly infusions of paclitaxel have
been associated with impressive clinical activity in both the primary and recurrent settings,
including patients with platinum and taxane-resistant disease [3, 16–21]. Previously, the
GOG has evaluated the clinical efficacy of weekly paclitaxel in this research queue (GOG
126-N). In that study of 48 platinum- and taxane-resistant ovarian cancer patients, 10 (21%)
were identified with a clinical response, including 2 complete responders [3]. The median
PFS and OS were not recorded in this publication, but were provided in a subsequent report
relating response and clinical benefit rates to PFS and OS [22]. In this report, the PFS and
OS for weekly paclitaxel were reported as 4.9 and 13.1 months, respectively. In addition, a
second multi-center trial of women with recurrent platinum- and taxane-resistant disease
required enrollment within 3 months of completion of primary therapy or re-exposure to
bolus infusion paclitaxel [20]. Among 36 measurable disease patients, 9 (25%) experienced
a response; PFS and OS for this study’s entire cohort of measurable and CA125 evaluable (n
= 15) patients was 5.5 months and 13.3 months, respectively.
In the absence of a randomized trial, it is difficult to compare the side effect profile of
weekly paclitaxel and weekly nab-paclitaxel; however, some notable observations can be
summarized. The infusion of nab-paclitaxel does not require premedication for the
prevention hypersensitivity reactions. As such, no HSRs were observed in our treatment
cohort. Secondly, while all taxane preparations have been associated with neurotoxicity, it is
clear the weekly schedule can significantly reduce its prevalence. In the current report, grade
3 neurotoxicity occurred in 1 patient (2%). This compares favorably with previously
reported rates of grade 3 to 4 neurotoxicity among patients treated with weekly paclitaxel
administered at lower doses, which have ranged from 4% to 11% [3, 17, 20, 23, 24].
Hypothesized mechanisms for clinical efficacy related to infusion schedule include more
frequent exposure to cell cycle specific cytotoxicity, dose intensity, endothelial cell
apoptosis and leveraged anti-angiogenesis. The mechanisms responsible for an anti-
angiogenesis effect are varied and include induction of thrombospondin-I, a known inhibitor
of VEGF ligand:receptor interaction, modulation of VEGF secretion, endothelial cell
apoptosis, regulation of local cytokines and most recently, the suppression of regulatory t
cells (Tregs) [25–35]. While this effect may be more closely tied to the agent, paclitaxel, than
to its schedule, more frequent exposure would take advantage of this mechanism [36]. It
would be anticipated that weekly taxane administration in combination with agents targeting
mechanisms of angiogenesis would have clinical merit as demonstrated in retrospective
clinical series [31, 37, 38].
Collectively, our data support the contention that weekly nab-paclitaxel is associated with
significant clinical efficacy in highly resistant ovarian cancer patients, and compared to
weekly paclitaxel in this setting, may have a more favorable side-effect profile.
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Table 1
Characteristics of Evaluable Patients (N=47)
Characteristic Number of Cases %
Age
 30–39 1 2.1
 40–49 8 17.0
 50–59 16 34.0
 60–69 15 31.9
 70–79 7 14.9
Race
 African American 9 19.1
 Hispanic 2 4.3
 American Indian 1 2.1
 White 35 74.5
Performance Status
 0 31 66.0
 1 15 31.9
 2 1 2.1
Site of Disease
 Ovary 41 87.2
 Fallopian tube 1 2.1
 Other 5 10.6
Cell Type
 Adenocarcinoma with Squamous Differentiation 1 2.1
 Adenocarcinoma, unspecified 4 8.5
 Clear Cell Carcinoma 4 8.5
 Endometrioid Adenocarcinoma 1 2.1
 Mucinous Adenocarcinoma 1 2.1
 Mixed Epithelial Carcinoma 1 2.1
 Adenosquamous 1 2.1
 Serous Adenocarcinoma 34 72.3
Grade
 1 7 14.9
 2 2 4.3
 3 38 80.9
Prior Chemotherapy
 1 Regimen 47 100.0
No Prior Radiation 47 100.0
Prior Immunotherapy
 No 45 95.7
 Yes 2 4.3
Prior Hormonal Therapy
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Characteristic Number of Cases %
 No 45 95.7
 Yes 2 4.3
Prior Surgery 47 100.0
Cycles of Treatment
 1 2 4.3
 2 16 34.0
 3 4 8.5
 4 4 8.5
 5 1 2.1
 6 6 12.8
 >6 14 29.8
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